Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update

Mesenchymal stromal cells (MSCs) are characterized by an extraordinary capacity to modulate the phenotype and functional properties of various immune cells that play an essential role in the pathogenesis of inflammatory disorders. Thus, MSCs efficiently impair the phagocytic and antigen-presenting c...

Full description

Bibliographic Details
Main Authors: Luise Müller, Antje Tunger, Manja Wobus, Malte von Bonin, Russell Towers, Martin Bornhäuser, Francesco Dazzi, Rebekka Wehner, Marc Schmitz
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.637725/full
id doaj-1e1d2d3802e6401c9a6a73cd97374963
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Luise Müller
Antje Tunger
Antje Tunger
Manja Wobus
Malte von Bonin
Malte von Bonin
Malte von Bonin
Russell Towers
Martin Bornhäuser
Martin Bornhäuser
Martin Bornhäuser
Martin Bornhäuser
Francesco Dazzi
Rebekka Wehner
Rebekka Wehner
Rebekka Wehner
Marc Schmitz
Marc Schmitz
Marc Schmitz
Marc Schmitz
spellingShingle Luise Müller
Antje Tunger
Antje Tunger
Manja Wobus
Malte von Bonin
Malte von Bonin
Malte von Bonin
Russell Towers
Martin Bornhäuser
Martin Bornhäuser
Martin Bornhäuser
Martin Bornhäuser
Francesco Dazzi
Rebekka Wehner
Rebekka Wehner
Rebekka Wehner
Marc Schmitz
Marc Schmitz
Marc Schmitz
Marc Schmitz
Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update
Frontiers in Cell and Developmental Biology
mesenchymal stromal cells
immunomodulation
macrophages
dendritic cells
T cells
author_facet Luise Müller
Antje Tunger
Antje Tunger
Manja Wobus
Malte von Bonin
Malte von Bonin
Malte von Bonin
Russell Towers
Martin Bornhäuser
Martin Bornhäuser
Martin Bornhäuser
Martin Bornhäuser
Francesco Dazzi
Rebekka Wehner
Rebekka Wehner
Rebekka Wehner
Marc Schmitz
Marc Schmitz
Marc Schmitz
Marc Schmitz
author_sort Luise Müller
title Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update
title_short Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update
title_full Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update
title_fullStr Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update
title_full_unstemmed Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update
title_sort immunomodulatory properties of mesenchymal stromal cells: an update
publisher Frontiers Media S.A.
series Frontiers in Cell and Developmental Biology
issn 2296-634X
publishDate 2021-02-01
description Mesenchymal stromal cells (MSCs) are characterized by an extraordinary capacity to modulate the phenotype and functional properties of various immune cells that play an essential role in the pathogenesis of inflammatory disorders. Thus, MSCs efficiently impair the phagocytic and antigen-presenting capacity of monocytes/macrophages and promote the expression of immunosuppressive molecules such as interleukin (IL)-10 and programmed cell death 1 ligand 1 by these cells. They also effectively inhibit the maturation of dendritic cells and their ability to produce proinflammatory cytokines and to stimulate potent T-cell responses. Furthermore, MSCs inhibit the generation and proinflammatory properties of CD4+ T helper (Th)1 and Th17 cells, while they promote the proliferation of regulatory T cells and their inhibitory capabilities. MSCs also impair the expansion, cytokine secretion, and cytotoxic activity of proinflammatory CD8+ T cells. Moreover, MSCs inhibit the differentiation, proliferation, and antibody secretion of B cells, and foster the generation of IL-10-producing regulatory B cells. Various cell membrane-associated and soluble molecules essentially contribute to these MSC-mediated effects on important cellular components of innate and adaptive immunity. Due to their immunosuppressive properties, MSCs have emerged as promising tools for the treatment of inflammatory disorders such as acute graft-versus-host disease, graft rejection in patients undergoing organ/cell transplantation, and autoimmune diseases.
topic mesenchymal stromal cells
immunomodulation
macrophages
dendritic cells
T cells
url https://www.frontiersin.org/articles/10.3389/fcell.2021.637725/full
work_keys_str_mv AT luisemuller immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT antjetunger immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT antjetunger immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT manjawobus immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT maltevonbonin immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT maltevonbonin immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT maltevonbonin immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT russelltowers immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT martinbornhauser immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT martinbornhauser immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT martinbornhauser immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT martinbornhauser immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT francescodazzi immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT rebekkawehner immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT rebekkawehner immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT rebekkawehner immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT marcschmitz immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT marcschmitz immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT marcschmitz immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
AT marcschmitz immunomodulatorypropertiesofmesenchymalstromalcellsanupdate
_version_ 1724277936458039296
spelling doaj-1e1d2d3802e6401c9a6a73cd973749632021-02-09T05:30:24ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2021-02-01910.3389/fcell.2021.637725637725Immunomodulatory Properties of Mesenchymal Stromal Cells: An UpdateLuise Müller0Antje Tunger1Antje Tunger2Manja Wobus3Malte von Bonin4Malte von Bonin5Malte von Bonin6Russell Towers7Martin Bornhäuser8Martin Bornhäuser9Martin Bornhäuser10Martin Bornhäuser11Francesco Dazzi12Rebekka Wehner13Rebekka Wehner14Rebekka Wehner15Marc Schmitz16Marc Schmitz17Marc Schmitz18Marc Schmitz19Institute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, GermanyInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, GermanyNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyDepartment of Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyDepartment of Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyGerman Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyDepartment of Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyGerman Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, GermanyCenter for Regenerative Therapies Dresden (CRTD), TU Dresden, Dresden, GermanySchool of Cancer and Pharmacological Sciences and KHP Cancer Research UK Centre, King’s College London, London, United KingdomInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, GermanyNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyGerman Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, GermanyInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, GermanyNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyGerman Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, GermanyCenter for Regenerative Therapies Dresden (CRTD), TU Dresden, Dresden, GermanyMesenchymal stromal cells (MSCs) are characterized by an extraordinary capacity to modulate the phenotype and functional properties of various immune cells that play an essential role in the pathogenesis of inflammatory disorders. Thus, MSCs efficiently impair the phagocytic and antigen-presenting capacity of monocytes/macrophages and promote the expression of immunosuppressive molecules such as interleukin (IL)-10 and programmed cell death 1 ligand 1 by these cells. They also effectively inhibit the maturation of dendritic cells and their ability to produce proinflammatory cytokines and to stimulate potent T-cell responses. Furthermore, MSCs inhibit the generation and proinflammatory properties of CD4+ T helper (Th)1 and Th17 cells, while they promote the proliferation of regulatory T cells and their inhibitory capabilities. MSCs also impair the expansion, cytokine secretion, and cytotoxic activity of proinflammatory CD8+ T cells. Moreover, MSCs inhibit the differentiation, proliferation, and antibody secretion of B cells, and foster the generation of IL-10-producing regulatory B cells. Various cell membrane-associated and soluble molecules essentially contribute to these MSC-mediated effects on important cellular components of innate and adaptive immunity. Due to their immunosuppressive properties, MSCs have emerged as promising tools for the treatment of inflammatory disorders such as acute graft-versus-host disease, graft rejection in patients undergoing organ/cell transplantation, and autoimmune diseases.https://www.frontiersin.org/articles/10.3389/fcell.2021.637725/fullmesenchymal stromal cellsimmunomodulationmacrophagesdendritic cellsT cells